Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Lenvatinib (off Label)

Lenvatinib + pembrolizumab

Eisai (investigator studies) · Phase 2 · Active, not recruiting · Enrollment 64

NCT04209660

Catalyst Primary completion. 12.2026. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy
Lenvatinib + pembrolizumabprogressive R/M ACC (n = 17 evaluable)not stated in sourceSingle armn/robjective response rate: 6%, ASCO 2023 (search record)